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Abstract 
Background: To compare the frequency of small 
for gestational age(SGA) babies between women 
treated with labetalol or methyldopa for pregnancy 
induced hypertension. 
Methods: In this randomized controlled trial 
patients were divided into Labetalol and 
Methyldopa groups. Both drugs were administered 
as oral preparation. Patients were followed during 
their pregnancy till their delivery time and then 
baby weight was checked at the time of delivery and 
plotted against gestational age to detect small for 
gestational age babies.  
Results: The frequency of SGA neonates was 
significantly higher in Group-A (labetalol) in 
comparison to Group-B. (Methyldopa) i.e. Group-A: 
37.8% vs. Group-B 13.3%(p-value=0.008). In all age 
groups i.e. <25years, 25-35years and >35 years, 
frequency of SGA was higher in Group-A (Labetalol 
group) women but statistical significance was not 
seen in any age group. There was no statistically 
significant  effect of parity on frequency of SGA. 
Women who were started treatment early  i-e at 20-
25weeks and 26-30weeks of gestation had more SGA 
babies in  Labetalol group(p=0.033,P=0.032)  . 
Although more number of SGA babies in Labetalol 
group were delivered at <34 weeks gestation but 
difference was not statistically significant (p=0.264) 
Conclusion: Methyldopa is more effective in 
pregnant women in terms of low incidence of small 
for gestational age babies as compared to labetalol. 
Key Words: Small for gestational age babies, 
Labetalol, Methyldopa, Pregnancy induced 
hypertension. 
Introduction 
Women having Pregnancy-induced hypertension have 
poor feto-maternal outcome as compared to 
normotensive women. Most commonly used drugs for 
treatment of pregnancy induced hypertension are 
methyldopa, combined alpha and beta blockers, beta 
blockers and calcium channel blockers. Studies have 
shown conflicting evidence about the foetal and 
maternal outcomes of these drugs during pregnancy. 
About 6-8% pregnancies are effected by pregnancy 
induced hypertension globally.1,2 Complications in the 
form of pre-eclampsia and eclampsia result in one 
death every three minute worldwide.3 Progression to 
adverse fetomaternal outcome can be prevented by 
using antihypertensive medicines. 4The purpose of 
giving antihypertensive drugs is to minimize the risk 
of severe hypertension ,stroke, cardiovascular strain, 
and kidney damage.5A number of drugs are being 
used for treatment of pregnancy induced 
hypertension. Internationally methyldopa, labetalol 
and nifedipine are recommended as drugs of first 
choice.6,7,8 
Since years, methyldopa is widely used in treatment of 
pregnancy induced hypertension.  Methyldopa 
decreases blood pressure by acting centrally on alpha 
2 receptors and by decreasing sympathetic nerve 
activity. 9,10 It takes 12-24 hoursfor adequate 
therapeutic response and large dose is required but it 
is helpful for long term control of blood pressure.11 
In comparison to other antihypertensive drugs, 
labetalol is more effective in lowering the blood 
pressure.12 Labetalol is a combined alpha- and beta-
blocker and contributes to a reduction in peripheral 
vascular resistance due to its additional arteriolar 
vasodilator effect, with little or no decline in cardiac 
output. Therefore, it has advantages over other beta 
blockers. The benefit of labetalol is that it can be 
injected and administered orally and acts rapidly than 
methyldopa. Now this is an established fact that beta 
blockers cross the placenta, enter in foetal circulation 
and may cause foetal bradycardia.13 
Evidence regarding perinatal outcomes of labetalol 
and methyldopa is controversial.9, 14, 15The purpose of 
our study was to compute the frequency of SGA 
babies in patients having pregnancy induced 
hypertension, treated with labetalol or methyldopa. 
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The actual birth weight below 10th percentile for 
gestational age (GA) is labelled as Small for gestational 
age (SGA). It increases the risk of intra-ventricular 
bleeding, neonatal convulsions, septicemia, 
necrotizing enterocolitis, cerebral palsy, duration of 
hospital stay and treatment cost.16,17In SGA babies, 
stillbirths and neonatal and infant mortality rate is 
higher as compared to appropriate for gestational 
age.18-22  We compared the age, parity and gestational 
age at start of treatment and at delivery,between the 
two treatment groups,to determine which factors 
effected the frequency of SGA. This study will help to 
set a protocol for the management of pregnancy 
induced hypertension by decreasing burden of small 
for gestational age neonates. 
 
Patients and Methods  
The study was carried out in Obstetrics and 
Gynaecology department of POF hospital Wah Cantt. 
It was a randomized controlled trial. Sample size was 
calculated by WHO sample size calculator. Total 90 
patients,45 in each group were included in study. 
Verbal informed consent was taken before inclusion in 
study. Patients who were given Labetalol were 
categorized as group A and those given methyldopa as 
group B. Patients having blood pressure 
≥140/90mmHg on two occasions at least 4h apart were 
part of study. Ages of patients were between 15-40 
years and had singleton pregnancy. Women having 
chronic hypertension, diabetes, cardiac or renal 
disease, malnutrition or any other medical disease 
were not part of this study. Sampling was done by 
non-probability consecutive sampling. Patients were 
randomized, by using computer generated sequence of 
random numbers, to either of two treatment arms-
Labetalol or methyldopa. Both the drugs were 
administered as oral preparation. The starting dose of 
Labetalol was 100mg BD up to a maximum of 
1.2gm/24hours.The staring dose of Methyldopa was 
250mg TDS up to a maximum of 2gm/24hours. The 
data was collected on a pre-designed proforma which 
included demographic details, gestational age at start 
of treatment and delivery, birth weight of baby .The 
patients were followed up during their pregnancy till 
delivery. The birth weight of baby was plotted against 
gestational age at delivery on growth chart, to 
determine whether the baby is appropriate or small for 
gestational age. Qualitative variables like parity, small 
for gestational age babies were measured as 
frequencies and percentages. Chi-square test was used 
for comparison of small for gestational age babies 
between two groups. P value <0.05 was considered 
statistically significant. 
 
Results 
Total 90 patients were included in the study, 45 
patients in each group. The patients in Group A were 
treatedwith Labetalol and group B with Methyldopa. 
The mean age of women in group A was 27.35±6.50 
years and in group B was 28.26±6.47 years. The mean 
gestational age at start of treatment was 30.26±4.26 
and 30.20±4.229 in group A and B respectively. The 
mean gestational age at delivery was 35.44±2.96 weeks 
in labetalol group and 36.04±2.60 weeks in 
methyldopa group. The mean birth weight of babies in 
group A was 2013.33±778.367gm and in group B was 
2311.11±779.92gm. A higher frequency of SGA babies 
was observed in women treated with labetalol (37.8%) 
than those treated with methyldopa(13.3%).The 
difference was significant statistically 
(p=0.008).Maximum number of patients were from the 
age group <25years (n=36, 40%) and 39.4% SGA cases 
were observed in this age group. On comparing the 
frequency of SGA with use of two drugs in different 
age groups, statistically difference was insignificant 
(Table 1).Among the two groups 38.8% (n=34) patients 
were primigravidas. When we compared the 
frequency of SGA was more in primigravidas who 
took labetalol (42.1%) but the difference was not 
statistically significant. (Table 2).Most cases of SGA 
were observed when the treatment was started at early 
gestation in both groups (Table 3). Babies in labetalol 
group were more affected in gestational age groups 
20-25wk and 26-30wk (p=0.033, P=0.032). No case of 
SGA was observed when treatment was started after 
35weeks of gestation (Table 3).Overall 23 (25.6%) 
patients delivered at <34wk gestation, 15 (33.3%) in 
labetalol group and 8 (17.7%) in methyldopa group. 
The frequency of SGA was more in labetalol group at 
<34 week and >34wweek gestation, as shown in table-
4 but not statistically significant (p=0.267, p=0.064) 
(Table 4). 
 
Table-1: Small for gestational age in treatment 
groups stratified for age of women   
Age Small for  
gestational  
age 
Labetalol 
Group 
Methyldopa 
Group 
p-value 
<25Y Yes 10(47.6%) 3(20%) 
0.082 
No 11(52.4%) 12(80%) 
25-
35y 
Yes 4(30.8%) 2(10%) 
0.134 
No 9(69.2%) 18(90%) 
>35Y Yes 3(27.3%) 1(10%) 
0.304 
No 8(72.7%) 9(90%) 
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Table-2:Small for gestational age in treatment 
groups stratified for parity of women 
Parity Small for  
gestational 
 age 
Labetalol 
Group 
Methyldopa 
Group 
p-
value 
Primigravida Yes 8(42%) 2(13.3%) 
0.06 
No 11(57.9%) 13(86.7%) 
Multigravida Yes 9(34.6%) 4(13.3%) 
0.058 No 17(65.4%) 26(86.7%) 
No 5(71.4%) 7(100%) 
Table 3: Treatment groups stratified for 
gestational age at start of treatment 
Gestational 
Age 
Small for  
gestational 
 age 
Labetalol 
Group 
Methyldopa 
Group 
p-value 
20-25 Yes 7(77.8%) 3(30%) 
0.033 
No 2(22.2%) 7(70%) 
26-30 Yes 8(53.3%) 2(15.4%) 
0.032 
No 7(46.7%) 11(84.6%) 
31-35 Yes 2(16.7%) 1(7.1%) 
0.477 
No 10(83.3%) 13(92.9%) 
>35 Yes 0(0%) 0(0%) 
- 
No 9(100%) 8(100%) 
Table 4: Small for gestational age in treatment 
groups stratified for  gestational age at delivery 
Gestational 
age at 
delivery 
Small for 
gestational 
age 
Group of drugs P-value 
Labetalol 
Group 
Methyldopa 
Group 
<34wk Yes 11 
(73.3%) 
4 (50%) 0.267 
No 4(26.7%) 4 (50%) 
>34wk Yes 6 (20%) 2 (5.4%) 0.064 
No 24 (80%) 35(94.6%) 
 
Discussion 
 Pregnancy induced hypertension is a major obstetrical 
problem even after so much advancement in field of 
medical science. Many drugs have been used to 
manage hypertensive disorders of pregnancy. Most 
commonly used drugs in Pakistan are beta-blockers, 
combined alpha and beta blockers, calcium channel 
blockers and centrally acting alpha agonist 
methyldopa. In the present study frequency of SGA 
babies was significantly higher in labetalol group 
(37.8%) as compared to methyldopa 
group(13.3%)(P=0.008).In a retrospective cohort study 
by Petersen KM frequency of SGA babies was 17.7% 
and 11.84% in labetalol and methyldopa group 21.  Xie 
RN in his study showed the rates of SGA babies for 
both<10th percentile (aOR=1.24) and <3rd percentile 
(aOR=0.99) were significantly higher among neonates 
of mothers who used beta-blockers in comparison to 
those who used methyldopa.14 CHIPS trial secondary 
analysis calculated SGA in 11.8% and 27% methyldopa 
treated  cases of pre-existing and gestational 
hypertension as compared to 20.9% and 21.7% 
labetalol treated cases of pre-existing and gestational 
hypertension(post-randomization group) and proved 
methyldopa was a better choice for patients with pre-
existing hypertension.23 Thakur V compared three 
drugs and calculated high frequency of low birth 
weight(<2.5kg) in methyldopa group (36%) as 
compared to labetalol(32%) and nifedipine (28%) but 
he did not find out whether these babies were small 
for gestational age or not.24 Molvi SN in his study 
showed that treatment with antihypertensive drugs 
decreased the frequency of SGA babies at delivery (p-
value= 0.033). i.e. Labetalol: 18% vs. Methyldopa: 
28.6% & Control: 40%.9  Molvi SN findings did not 
support our results as in his study more number of 
SGA babies belonged to methyldopa and control 
group as compared to labetalol group. 
A local study from Pakistan suggested that labetalol 
has better antihypertensive effects than methyldopa 
treatment, fewer maternal and fetal side effects, and 
established that it is drug of choice for pregnancy-
induced hypertension.But they did not studySGA in 
both treatment groups.15 
Majority of women (n=36 40%) were<25y, a finding 
similar to study of Babbar K (60% <25y).25 The 
frequency of SGA babies was higher in women <25 
years of age but when compared in both groups the 
difference was not statistically significant (P=0.082). 
The SGA babies frequency was higher in both 
primigravidas and multigravidas in labetalol group, 
reflecting Parity did not affect significantly. Starting 
treatment at an early gestation increased frequency of 
SGA in both groups, but affected labetalol group more 
significantly (P=0.033, P=0.032 at 20-25wk &26-30wk 
respectively).  In our study 33.3% and 18.9% cases in 
labetalol and methyldopa group delivered at <34wk 
gestation, although non-significant statistically 
(p=0.267). This finding supported by CHIPS trial 
where 24% and 18.9% cases of gestational 
hypertension post-randomization in labetalol group 
and methyldopa group delivered at <34wk gestation 
(aOR0.97), indicating an increased risk of 
delivery<34wk in labetalol group.23 
Antihypertensive drugs have a vital role in controlling 
blood pressure in pregnant women. In determining the 
treatment plan, practitioners must pay attention to the 
severity of maternal hypertension, the duration of 
pregnancy, the efficacy and side effects of the 
individual drugs.Results of this study indicate that 
Methyldopa as compared to Labetalol is more effective 
in pregnant women in reducing the frequency of small 
for gestational age babies. The most important 
responsibility of obstetricians is to carefully select drug 
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therapies and to consider the effectiveness as well as 
safety of the drug for mother and fetus. 
 
Conclusion 
Methyldopa is more effective in pregnant women in 
terms of low incidence of small for gestational age 
babies as compared to labetalol. 
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